391 related articles for article (PubMed ID: 33768452)
1. Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.
Juhlin CC
Endocr Pathol; 2021 Jun; 32(2):228-244. PubMed ID: 33768452
[TBL] [Abstract][Full Text] [Related]
2. A Guide to Pheochromocytomas and Paragangliomas.
Guilmette J; Sadow PM
Surg Pathol Clin; 2019 Dec; 12(4):951-965. PubMed ID: 31672301
[TBL] [Abstract][Full Text] [Related]
3. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
4. [Pathologist contribution in the diagnosis of hereditary predisposition to paranganglioma and pheochromocytoma].
Broudin C; Favier J; Verkarre V; Méatchi T
Ann Pathol; 2020 Apr; 40(2):134-141. PubMed ID: 32146049
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.
Garcia-Carbonero R; Matute Teresa F; Mercader-Cidoncha E; Mitjavila-Casanovas M; Robledo M; Tena I; Alvarez-Escola C; Arístegui M; Bella-Cueto MR; Ferrer-Albiach C; Hanzu FA
Clin Transl Oncol; 2021 Oct; 23(10):1995-2019. PubMed ID: 33959901
[TBL] [Abstract][Full Text] [Related]
6. Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma.
Jiang J; Zhang J; Pang Y; Bechmann N; Li M; Monteagudo M; Calsina B; Gimenez-Roqueplo AP; Nölting S; Beuschlein F; Fassnacht M; Deutschbein T; Timmers HJLM; Åkerström T; Crona J; Quinkler M; Fliedner SMJ; Liu Y; Guo J; Li X; Guo W; Hou Y; Wang C; Zhang L; Xiao Q; Liu L; Gao X; Burnichon N; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32750708
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
Khatami F; Mohammadamoli M; Tavangar SM
Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic approach of pheochromocytomas and paragangliomas].
Gómez RM; Hernaiz M; de Miguel V; Aparicio LS; Marín MJ; Lupi S; Barontini M;
Hipertens Riesgo Vasc; 2019; 36(1):34-43. PubMed ID: 30078655
[TBL] [Abstract][Full Text] [Related]
9. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
10. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
Stenman A; Zedenius J; Juhlin CC
Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
[TBL] [Abstract][Full Text] [Related]
11. What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?
Papathomas TG; Suurd DPD; Pacak K; Tischler AS; Vriens MR; Lam AK; de Krijger RR
Endocr Pathol; 2021 Mar; 32(1):134-153. PubMed ID: 33433885
[TBL] [Abstract][Full Text] [Related]
12. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
13. Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and Paraganglioma.
Cheung VKY; Gill AJ; Chou A
Endocr Pathol; 2018 Jun; 29(2):169-175. PubMed ID: 29779206
[TBL] [Abstract][Full Text] [Related]
14. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.
Crona J; Taïeb D; Pacak K
Endocr Rev; 2017 Dec; 38(6):489-515. PubMed ID: 28938417
[TBL] [Abstract][Full Text] [Related]
15. Pheochromocytoma and paraganglioma: imaging characteristics.
Baez JC; Jagannathan JP; Krajewski K; O'Regan K; Zukotynski K; Kulke M; Ramaiya NH
Cancer Imaging; 2012 May; 12(1):153-62. PubMed ID: 22571874
[TBL] [Abstract][Full Text] [Related]
16. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
Evenepoel L; van Nederveen FH; Oudijk L; Papathomas TG; Restuccia DF; Belt EJT; de Herder WW; Feelders RA; Franssen GJH; Hamoir M; Maiter D; Ghayee HK; Shay JW; Perren A; Timmers HJLM; van Eeden S; Vroonen L; Aydin S; Robledo M; Vikkula M; de Krijger RR; Dinjens WNM; Persu A; Korpershoek E
J Clin Endocrinol Metab; 2018 Jan; 103(1):46-55. PubMed ID: 28938490
[TBL] [Abstract][Full Text] [Related]
17. Update on Paragangliomas and Pheochromocytomas.
Lam AK
Turk Patoloji Derg; 2015; 31 Suppl 1():105-12. PubMed ID: 26177321
[TBL] [Abstract][Full Text] [Related]
18. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms.
Stenman A; Zedenius J; Juhlin CC
Langenbecks Arch Surg; 2018 Sep; 403(6):785-790. PubMed ID: 29779047
[TBL] [Abstract][Full Text] [Related]
19. Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.
Jain A; Baracco R; Kapur G
Pediatr Nephrol; 2020 Apr; 35(4):581-594. PubMed ID: 30603807
[TBL] [Abstract][Full Text] [Related]
20. Molecular markers of paragangliomas/pheochromocytomas.
Zhikrivetskaya SO; Snezhkina AV; Zaretsky AR; Alekseev BY; Pokrovsky AV; Golovyuk AL; Melnikova NV; Stepanov OA; Kalinin DV; Moskalev AA; Krasnov GS; Dmitriev AA; Kudryavtseva AV
Oncotarget; 2017 Apr; 8(15):25756-25782. PubMed ID: 28187001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
